A Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination with Durvalumab (MEDI4736) orDurvalumab (MEDI4736) + Chemotherapy in Untreated Patients with Advanced or MetastaticAdenocarcinoma Non-Small Cell Lung Cancer

Project: Research project

Project Details

Description

A Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination with Durvalumab (MEDI4736) or Durvalumab (MEDI4736) + Chemotherapy in Untreated Patients with Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer
StatusActive
Effective start/end date9/16/19 → 9/30/25

Funding

  • ASTRAZENECA

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint